Covered recipient · General Payments record
PHILLIP J GOLDSTEIN
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$3,156.46
91 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,634.03 | 87 |
| Travel and Lodging | $1,122.43 | 3 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $400.00 | 1 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Adare Pharmaceuticals, Inc. | $1,444.94 | 5 |
| QOL Medical, LLC | $533.92 | 10 |
| AbbVie Inc. | $430.71 | 28 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $263.39 | 17 |
| Janssen Biotech, Inc. | $90.50 | 6 |
| Gilead Sciences, Inc. | $70.67 | 4 |
| RedHill Biopharma Inc. | $68.72 | 3 |
| Takeda Pharmaceuticals U.S.A., Inc. | $49.08 | 3 |
| Ferring Pharmaceuticals Inc. | $41.87 | 3 |
| Allergan, Inc. | $40.07 | 3 |
| Merck Sharp & Dohme Corporation | $23.51 | 2 |
| IRONWOOD PHARMACEUTICALS, INC | $22.77 | 2 |
| Nestle HealthCare Nutrition Inc. | $21.51 | 1 |
| Romark Laboratories, LC | $16.65 | 1 |
| Intercept Pharmaceuticals, Inc. | $14.52 | 1 |
| UCB, Inc. | $12.65 | 1 |
| EVOKE PHARMA, INC. | $10.98 | 1 |
Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
PHILLIP J GOLDSTEIN
NPI 1346406147 · CMS profile ID 715307
Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
GREENVILLE, NC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1346406147?year=2020&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- PHILLIP J GOLDSTEIN, NPI 1346406147, CMS profile ID 715307. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346406147?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). PHILLIP J GOLDSTEIN, NPI 1346406147, CMS profile ID 715307. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346406147?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- PHILLIP J GOLDSTEIN, NPI 1346406147, CMS profile ID 715307, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1346406147?year=2020&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
91 matching records · $3,156.46 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–91 of 91.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| QOL Medical, LLC | $400.00 | 06/03/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 731212571 | CMS |
| QOL Medical, LLC | $17.70 | 06/01/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 731212495 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.18 | 05/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 737532051 | CMS |
| AbbVie Inc. | $8.95 | 05/14/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721827053 | CMS |
| QOL Medical, LLC | $16.60 | 05/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 731212499 | CMS |
| AbbVie Inc. | $20.08 | 05/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721827049 | CMS |
| Romark Laboratories, LC | $16.65 | 04/24/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749989751 | CMS |
| QOL Medical, LLC | $9.59 | 04/08/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 731212507 | CMS |
| Allergan, Inc. | $14.20 | 03/16/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723439131 | CMS |
| AbbVie Inc. | $13.24 | 03/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721827045 | CMS |
| AbbVie Inc. | $14.82 | 03/09/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721827041 | CMS |
| Merck Sharp & Dohme Corporation | $11.72 | 03/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747713009 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.24 | 03/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 737532049 | CMS |
| Janssen Biotech, Inc. | $11.05 | 03/03/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719354625 | CMS |
| AbbVie Inc. | $11.26 | 03/01/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721827037 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.26 | 02/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 737532047 | CMS |
| AbbVie Inc. | $16.74 | 02/20/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721827033 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $12.08 | 02/20/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 737532043 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $0.49 | 02/20/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 737532045 | CMS |
| AbbVie Inc. | $51.10 | 02/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721827029 | CMS |
| IRONWOOD PHARMACEUTICALS, INC | $11.48 | 02/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749790377 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $10.81 | 02/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 737532041 | CMS |
| AbbVie Inc. | $12.57 | 02/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721827025 | CMS |
| QOL Medical, LLC | $6.90 | 02/06/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 731212547 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $11.30 | 01/31/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747174765 | CMS |
| AbbVie Inc. | $19.34 | 01/29/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721827021 | CMS |
| AbbVie Inc. | $10.59 | 01/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721827017 | CMS |
| Gilead Sciences, Inc. | $20.13 | 01/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747970393 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.60 | 01/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 737532039 | CMS |
| AbbVie Inc. | $20.15 | 01/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721827013 | CMS |
| Allergan, Inc. | $13.50 | 01/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723439129 | CMS |
| UCB, Inc. | $12.65 | 01/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 746061919 | CMS |
| Adare Pharmaceuticals, Inc. | $219.52 | 01/12/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750444397 | CMS |
| Adare Pharmaceuticals, Inc. | $219.52 | 01/12/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750444399 | CMS |
| Adare Pharmaceuticals, Inc. | $170.49 | 01/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750444325 | CMS |
| Adare Pharmaceuticals, Inc. | $683.39 | 01/11/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750444393 | CMS |
| Adare Pharmaceuticals, Inc. | $152.02 | 01/09/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 750444323 | CMS |
| Merck Sharp & Dohme Corporation | $11.79 | 01/08/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747644381 | CMS |
| AbbVie Inc. | $17.47 | 01/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721827009 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.97 | 01/06/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747174759 | CMS |
| AbbVie Inc. | $12.97 | 01/02/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721827005 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $168,298.94 | 72 |
| PY2024 | Principal investigator | $202,773.78 | 41 |
| PY2023 | Principal investigator | $223,446.84 | 48 |
| PY2022 | Principal investigator | $60,191.58 | 23 |
| PY2021 | Recipient | $4,599.00 | 1 |
| PY2021 | Principal investigator | $137,081.86 | 30 |
| PY2020 | Recipient | $693.52 | 4 |
| PY2020 | Principal investigator | $247,920.22 | 46 |
| PY2019 | Recipient | $2,453.31 | 2 |
| PY2019 | Principal investigator | $339,148.14 | 49 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
72 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,738.00 | 12/11/2025 | Non-covered Recipient Entity CAROLINA RESEARCH | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure | No dispute reported | 06/30/2026 | 1244051831 |
| Principal investigator 1 | ABBVIE INC. | $2,824.90 | 12/04/2025 | Non-covered Recipient Entity CAROLINA DIGESTIVE DISEASES | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202527334 |
| Principal investigator 1 | Eli Lilly and Company | $4,750.00 | 12/03/2025 | Non-covered Recipient Entity RESEARCH ALLIANCE INC | MIRIKIZUMAB LY3074828 PRO UC CD - OMVOH - ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1187890380 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $46.64 | 11/19/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220780102 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 11/19/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220780104 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.00 | 11/19/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220780106 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $69.96 | 11/19/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220780150 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $292.00 | 11/19/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220780152 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.00 | 11/19/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220780154 |
| Principal investigator 1 | ABBVIE INC. | $3,375.00 | 11/12/2025 | Non-covered Recipient Entity CAROLINA DIGESTIVE DISEASES | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202523817 |
| Principal investigator 1 | ABBVIE INC. | $3,402.10 | 11/04/2025 | Non-covered Recipient Entity CAROLINA DIGESTIVE DISEASES | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202520197 |
| Principal investigator 1 | ABBVIE INC. | $3,073.20 | 10/09/2025 | Non-covered Recipient Entity CAROLINA DIGESTIVE DISEASES | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202514235 |
| Principal investigator 1 | ABBVIE INC. | $8,700.90 | 10/01/2025 | Non-covered Recipient Entity CAROLINA DIGESTIVE DISEASES | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202512922 |
| Principal investigator 1 | ABBVIE INC. | $3,286.40 | 09/03/2025 | Non-covered Recipient Entity CAROLINA DIGESTIVE DISEASES | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202507303 |
| Principal investigator 1 | ABBVIE INC. | $1,978.99 | 08/26/2025 | Non-covered Recipient Entity CAROLINA RESEARCH | A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202505899 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $46.64 | 08/26/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220780094 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.86 | 08/26/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220780096 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $438.00 | 08/26/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220780098 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.00 | 08/26/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220780100 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $69.96 | 08/26/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220780142 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $199.80 | 08/26/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220780144 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $547.50 | 08/26/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220780146 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.00 | 08/26/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220780148 |
| Principal investigator 1 | Genentech, Inc. | $2,471.00 | 08/26/2025 | Non-covered Recipient Entity CAROLINA RESEARCH | vixarelimab ulcerative colitis study | No dispute reported | 06/30/2026 | 1211583960 |
| Principal investigator 1 | ABBVIE INC. | $2,772.90 | 08/05/2025 | Non-covered Recipient Entity CAROLINA DIGESTIVE DISEASES | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202501422 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 07/28/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220780090 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 07/28/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220780092 |
| Principal investigator 1 | ABBVIE INC. | $530.40 | 07/10/2025 | Non-covered Recipient Entity CAROLINA DIGESTIVE DISEASES | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202497912 |
| Principal investigator 1 | ABBVIE INC. | $1,589.90 | 07/02/2025 | Non-covered Recipient Entity CAROLINA DIGESTIVE DISEASES | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202495245 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,403.00 | 07/02/2025 | Non-covered Recipient Entity CAROLINA RESEARCH | A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223282046 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $15,871.90 | 07/02/2025 | Non-covered Recipient Entity CAROLINA RESEARCH | A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223282054 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,362.00 | 07/02/2025 | Non-covered Recipient Entity CAROLINA RESEARCH | A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223282132 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,668.00 | 07/02/2025 | Non-covered Recipient Entity CAROLINA RESEARCH | A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223282138 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 06/24/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220780140 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,500.00 | 06/23/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220780084 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,534.00 | 06/23/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220780086 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $700.00 | 06/23/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220780088 |
| Principal investigator 1 | Genentech, Inc. | $8,303.00 | 06/20/2025 | Non-covered Recipient Entity CAROLINA RESEARCH | vixarelimab ulcerative colitis study | No dispute reported | 06/30/2026 | 1211583951 |
| Principal investigator 1 | Genentech, Inc. | $9,716.10 | 06/20/2025 | Non-covered Recipient Entity CAROLINA RESEARCH | vixarelimab ulcerative colitis study | No dispute reported | 06/30/2026 | 1211583955 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,120.00 | 06/20/2025 | Non-covered Recipient Entity CAROLINA RESEARCH | A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223281670 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,280.00 | 06/20/2025 | Non-covered Recipient Entity CAROLINA RESEARCH | A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223281672 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $574.00 | 06/20/2025 | Non-covered Recipient Entity CAROLINA RESEARCH | A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223281674 |
| Principal investigator 1 | ABBVIE INC. | $7,524.40 | 06/03/2025 | Non-covered Recipient Entity CAROLINA DIGESTIVE DISEASES | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202488869 |
| Principal investigator 1 | ABBVIE INC. | $8,895.90 | 05/14/2025 | Non-covered Recipient Entity CAROLINA DIGESTIVE DISEASES | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202484861 |
| Principal investigator 1 | ABBVIE INC. | $8,700.90 | 04/23/2025 | Non-covered Recipient Entity CAROLINA DIGESTIVE DISEASES | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202478606 |
| Principal investigator 1 | ABBVIE INC. | $11,037.00 | 04/03/2025 | Non-covered Recipient Entity CAROLINA RESEARCH | A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) | No dispute reported | 06/30/2026 | 1202471464 |
| Principal investigator 1 | ABBVIE INC. | $3,374.80 | 04/03/2025 | Non-covered Recipient Entity CAROLINA DIGESTIVE DISEASES | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202471467 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $8.83 | 03/10/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | Proof of Clinical Principal in Crohn's Disease | No dispute reported | 06/30/2026 | 1220998971 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $700.00 | 03/06/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220780124 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,534.00 | 03/06/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220780126 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,500.00 | 03/06/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220780128 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $209.88 | 02/25/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220780074 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.86 | 02/25/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220780076 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $730.00 | 02/25/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220780078 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $58.62 | 02/25/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220780080 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.00 | 02/25/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220780082 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $209.88 | 02/25/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220780130 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.86 | 02/25/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220780132 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $730.00 | 02/25/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220780134 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $58.62 | 02/25/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220780136 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.00 | 02/25/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220780138 |
| Principal investigator 1 | Eli Lilly and Company | $92.75 | 02/25/2025 | Non-covered Recipient Entity RESEARCH ALLIANCE INC | A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE | No dispute reported | 06/30/2026 | 1187890616 |
| Principal investigator 1 | Eli Lilly and Company | $15,170.00 | 02/11/2025 | Non-covered Recipient Entity RESEARCH ALLIANCE INC | A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE | No dispute reported | 06/30/2026 | 1187889574 |
| Principal investigator 1 | ABBVIE INC. | $1,589.90 | 02/06/2025 | Non-covered Recipient Entity CAROLINA DIGESTIVE DISEASES | M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202446975 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.50 | 01/24/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220780108 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.50 | 01/24/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220780110 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.37 | 01/24/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220780112 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.14 | 01/24/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220780114 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.86 | 01/24/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220780116 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $21.43 | 01/24/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220780118 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $239.89 | 01/24/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220780120 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.52 | 01/24/2025 | Non-covered Recipient Entity Carolina Digestive Diseases PA | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220780122 |